{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:23:04Z","timestamp":1791321784703,"version":"4.3.1"},"reference-count":205,"publisher":"Informa UK Limited","issue":"9","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.2217\/imt.13.94","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T15:47:47Z","timestamp":1378136867000},"page":"955-974","source":"Crossref","is-referenced-by-count":109,"title":["Current Immunotherapy in Rheumatoid Arthritis"],"prefix":"10.1080","volume":"5","author":[{"given":"Florian MP","family":"Meier","sequence":"first","affiliation":[{"name":"Department of Internal Medicine &amp; Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Frerix","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine &amp; Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Hermann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine &amp; Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine &amp; Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01202a519"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.27.1.64"},{"key":"e_1_3_2_3_5_1","first-page":"CD000957","volume":"2","author":"Suarez-Almazor ME","year":"2000","unstructured":"Suarez-Almazor ME , BelseckE, SheaB, WellsG, TugwellP. Methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev.2 , CD000957 (2000).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24219"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem279"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10712"},{"issue":"1","key":"e_1_3_2_3_10_1","first-page":"36","volume":"25","author":"Ortiz Z","year":"1998","unstructured":"Ortiz Z , SheaB, Suarez-AlmazorME, MoherD, WellsGA, TugwellP. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials. J. Rheumatol.25(1) , 36\u201343 (1998).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-489"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198503283121303"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280702"},{"issue":"12","key":"e_1_3_2_3_14_1","first-page":"1628","volume":"17","author":"Furst DE","year":"1990","unstructured":"Furst DE , EriksonN, CluteL, KoehnkeR, BurmeisterLF, KohlerJA. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J. Rheumatol.17(12) , 1628\u20131635 (1990).","journal-title":"J. Rheumatol."},{"issue":"2","key":"e_1_3_2_3_15_1","first-page":"91","volume":"39","author":"Pinheiro GR","year":"1993","unstructured":"Pinheiro GR , Helfenstein J\u00fanior M, Ferraz MB, Atra E. [A short-term randomized controlled study with methotrexate in rheumatoid arthritis]. Rev. Assoc. Med. Bras.39(2) , 91\u201394 (1993).","journal-title":"Rev. Assoc. Med. Bras."},{"issue":"8","key":"e_1_3_2_3_16_1","first-page":"1631","volume":"29","author":"Aletaha D","year":"2002","unstructured":"Aletaha D , SmolenJS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J. Rheumatol.29(8) , 1631\u20131638 (2002).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092668"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23144"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.21.2542"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201162"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4777"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2000.00296.x"},{"issue":"6","key":"e_1_3_2_3_24_1","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.","volume":"30","author":"Osiri M","year":"2003","unstructured":"Osiri M , SheaB, RobinsonVet al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J. Rheumatol. 30(6) , 1182\u20131190 (2003).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_25_1","first-page":"CD002047","article-title":"Leflunomide for treating rheumatoid arthritis.","volume":"1","author":"Osiri M","year":"2003","unstructured":"Osiri M , SheaB, RobinsonVet al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 1 , CD002047 (2003).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09403-3"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.6.655"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.10.913"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381111"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550010-00009"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.3.382"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(01)00186-2"},{"issue":"4","key":"e_1_3_2_3_35_1","first-page":"612","volume":"21","author":"Imai F","year":"1994","unstructured":"Imai F , SuzukiT, IshibashiT, TanakaM, AkiyamaY, DohiY. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. J. Rheumatol.21(4) , 612\u2013615 (1994).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI992"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.62.6.817"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1941::AID-ANR4>3.0.CO;2-O"},{"issue":"10","key":"e_1_3_2_3_39_1","first-page":"2123","article-title":"Sulfasalazine treatment for rheumatoid arthritis: a meta-analysis of 15 randomized trials.","volume":"26","author":"Weinblatt ME","year":"1999","unstructured":"Weinblatt ME , RedaD, HendersonWet al. Sulfasalazine treatment for rheumatoid arthritis: a meta-analysis of 15 randomized trials. J. Rheumatol. 26(10) , 2123\u20132130 (1999).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_40_1","first-page":"CD000958","volume":"2","author":"Suarez-Almazor ME","year":"2000","unstructured":"Suarez-Almazor ME , BelseckE, SheaB, WellsG, TugwellP. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst. Rev.2 , CD000958 (2000).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92442-2"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/11596240-000000000-00000"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.2.196"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.6.566"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21018"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s003930170065"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-011-1286-z"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27409"},{"issue":"5","key":"e_1_3_2_3_49_1","first-page":"683","volume":"20","author":"Wang ZY","year":"2002","unstructured":"Wang ZY , MorinobuA, KawanoS, SaegusaJ, WangB, KumagaiS. Gold sodium thiomalate suppresses the differentiation and function of human dendritic cells from peripheral blood monocytes. Clin. Exp. Rheumatol.20(5) , 683\u2013688 (2002).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_3_50_1","first-page":"CD000520","article-title":"Injectable gold for rheumatoid arthritis.","volume":"2","author":"Clark P","year":"2000","unstructured":"Clark P , TugwellP, BennetKet al. Injectable gold for rheumatoid arthritis. Cochrane Database Syst. Rev. 2 , CD000520 (2000).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.3.169"},{"key":"e_1_3_2_3_52_1","first-page":"CD000959","volume":"4","author":"Suarez-Almazor ME","year":"2000","unstructured":"Suarez-Almazor ME , BelseckE, SheaB, HomikJ, WellsG, TugwellP. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst. Rev.4 , CD000959 (2000).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834456bf"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.3.1122"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90771-V"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.10.582"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20133"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094474"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60027-0"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605163342002"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10228"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099861"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3060"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)08513-4"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34498"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60944-2"},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303006"},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.8.892"},{"issue":"8","key":"e_1_3_2_3_69_1","first-page":"1521","article-title":"Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.","volume":"31","author":"Kremer J","year":"2004","unstructured":"Kremer J , GenoveseM, CannonGWet al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J. Rheumatol. 31(8) , 1521\u20131531 (2004).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-9-200211050-00007"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0482-50042011000200004"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P"},{"key":"e_1_3_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350304"},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780361006"},{"key":"e_1_3_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330301"},{"key":"e_1_3_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401018"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21796"},{"key":"e_1_3_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.4.291"},{"issue":"3","key":"e_1_3_2_3_79_1","first-page":"486","volume":"33","author":"Karanikolas G","year":"2006","unstructured":"Karanikolas G , CharalambopoulosD, AndrianakosA, AntoniadesC, KatsilambrosN. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J. Rheumatol.33(3) , 486\u2013489 (2006).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.11.1049"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.4.220"},{"key":"e_1_3_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057133"},{"key":"e_1_3_2_3_83_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009749409103721"},{"issue":"10","key":"e_1_3_2_3_84_1","first-page":"2077","volume":"29","author":"Carmichael SJ","year":"2002","unstructured":"Carmichael SJ , BealJ, DayRO, TettSE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J. Rheumatol.29(10) , 2077\u20132083 (2002).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350802"},{"key":"e_1_3_2_3_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381213"},{"key":"e_1_3_2_3_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21620"},{"key":"e_1_3_2_3_88_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-005-0420-z"},{"key":"e_1_3_2_3_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016709"},{"key":"e_1_3_2_3_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009749950155571"},{"key":"e_1_3_2_3_91_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.52.10.711"},{"key":"e_1_3_2_3_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"},{"key":"e_1_3_2_3_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60132-4"},{"key":"e_1_3_2_3_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_3_2_3_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.014"},{"key":"e_1_3_2_3_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq316"},{"key":"e_1_3_2_3_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.02.001"},{"key":"e_1_3_2_3_98_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.091391"},{"key":"e_1_3_2_3_99_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R203"},{"key":"e_1_3_2_3_100_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030275"},{"key":"e_1_3_2_3_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.4"},{"key":"e_1_3_2_3_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200838"},{"issue":"1","key":"e_1_3_2_3_103_1","first-page":"31","volume":"30","author":"Markatseli TE","year":"2012","unstructured":"Markatseli TE , AlamanosY, SaougouI, VoulgariPV, DrososAA. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin. Exp. Rheumatol.30(1) , 31\u201338 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_3_104_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111125"},{"key":"e_1_3_2_3_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092833"},{"key":"e_1_3_2_3_106_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker124"},{"key":"e_1_3_2_3_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065615"},{"key":"e_1_3_2_3_108_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"e_1_3_2_3_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227"},{"key":"e_1_3_2_3_110_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001395"},{"key":"e_1_3_2_3_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701607067"},{"key":"e_1_3_2_3_112_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200956"},{"key":"e_1_3_2_3_113_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.008"},{"key":"e_1_3_2_3_114_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.608655"},{"key":"e_1_3_2_3_115_1","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview.","volume":"2","author":"Singh JA","year":"2011","unstructured":"Singh JA , WellsGA, ChristensenRet al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2 , CD008794 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90185-7"},{"key":"e_1_3_2_3_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem072"},{"key":"e_1_3_2_3_118_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2143"},{"key":"e_1_3_2_3_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23119"},{"key":"e_1_3_2_3_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21901"},{"key":"e_1_3_2_3_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05159.x"},{"key":"e_1_3_2_3_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34409"},{"key":"e_1_3_2_3_123_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"e_1_3_2_3_124_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.200504"},{"key":"e_1_3_2_3_125_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.649327"},{"key":"e_1_3_2_3_126_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0111-7"},{"key":"e_1_3_2_3_127_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200003"},{"key":"e_1_3_2_3_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.06.005"},{"key":"e_1_3_2_3_129_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S32244"},{"key":"e_1_3_2_3_130_1","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.","author":"van Vollenhoven RF","year":"2012","unstructured":"van Vollenhoven RF , EmeryP, BinghamCOet al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. (2012) (Epub ahead of print).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_3_131_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.103"},{"key":"e_1_3_2_3_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34468"},{"key":"e_1_3_2_3_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"e_1_3_2_3_134_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080002"},{"key":"e_1_3_2_3_135_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111345"},{"key":"e_1_3_2_3_136_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201102400136"},{"key":"e_1_3_2_3_137_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1349-y"},{"key":"e_1_3_2_3_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_3_2_3_139_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_3_2_3_140_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_3_2_3_141_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033"},{"key":"e_1_3_2_3_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2009.12.002"},{"key":"e_1_3_2_3_143_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.132134"},{"key":"e_1_3_2_3_144_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201612"},{"key":"e_1_3_2_3_145_1","author":"Karlsson JA","year":"2012","unstructured":"Karlsson JA , NeoviusM, Nilsson J\u00c5 et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Ann. Rheum. Dis. (2012) (Epub ahead of print).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_3_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"e_1_3_2_3_147_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050524"},{"key":"e_1_3_2_3_148_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_3_2_3_149_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20115"},{"key":"e_1_3_2_3_150_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes217"},{"key":"e_1_3_2_3_151_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200490"},{"key":"e_1_3_2_3_152_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S36707"},{"key":"e_1_3_2_3_153_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200228"},{"key":"e_1_3_2_3_154_1","doi-asserted-by":"publisher","DOI":"10.2165\/11594990-000000000-00000"},{"key":"e_1_3_2_3_155_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100665"},{"key":"e_1_3_2_3_156_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.1209"},{"key":"e_1_3_2_3_157_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37820"},{"key":"e_1_3_2_3_158_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-968-6_1"},{"key":"e_1_3_2_3_159_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1206315"},{"key":"e_1_3_2_3_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61722-X"},{"key":"e_1_3_2_3_161_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-011-0877-4"},{"key":"e_1_3_2_3_162_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S25426"},{"key":"e_1_3_2_3_163_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24264"},{"key":"e_1_3_2_3_164_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11227"},{"key":"e_1_3_2_3_165_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104802"},{"key":"e_1_3_2_3_166_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24266"},{"key":"e_1_3_2_3_167_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24485"},{"key":"e_1_3_2_3_168_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100602"},{"key":"e_1_3_2_3_169_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1701"},{"key":"e_1_3_2_3_170_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.119479"},{"key":"e_1_3_2_3_171_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34489"},{"key":"e_1_3_2_3_172_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150284"},{"key":"e_1_3_2_3_173_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3333"},{"key":"e_1_3_2_3_174_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34329"},{"key":"e_1_3_2_3_175_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2365"},{"key":"e_1_3_2_3_176_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"e_1_3_2_3_177_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_3_2_3_178_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"e_1_3_2_3_179_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"e_1_3_2_3_180_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108159"},{"key":"e_1_3_2_3_181_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_3_2_3_182_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_3_2_3_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_3_2_3_184_1","first-page":"S548","volume":"64","author":"Wollenhaupt J","year":"2012","unstructured":"Wollenhaupt J , SilverfieldJC, LeeEB. Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 48 months. Arthritis Rheum.64(Suppl.10) , S548\u2013S549 (2012).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_3_185_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200408"},{"key":"e_1_3_2_3_186_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200493"},{"key":"e_1_3_2_3_187_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"e_1_3_2_3_188_1","first-page":"S1049","volume":"64","author":"Genovese MC","year":"2012","unstructured":"Genovese MC , KeystoneE, TaylorPC. 24-week results of a blinded Phase 2b dose-ranging study of baricitinib, an oral janus kinase 1\/januse kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum.64(Suppl. 10) , S1049\u2013S1050 (2012).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_3_189_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_2_3_190_1","first-page":"S1051","volume":"64","author":"Vanhouette F","year":"2012","unstructured":"Vanhouette F , MazurM, van der Aa A. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634. Arthritis Rheum.64(Suppl. 10) , S1051 (2012).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_3_191_1","first-page":"S569","volume":"64","author":"Zhu T","year":"2012","unstructured":"Zhu T , OdaK, ValluriU. Coadministration of ASP015K, a novel janus kinase inhibitor with methotrexate demonstrates tolerability and lack of pharmaco-kinetic interactions in patients with rheumatoid arthritis. Arthritis Rheum.64(Suppl. 10) , S569 (2012).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_3_192_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30114"},{"key":"e_1_3_2_3_193_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23992"},{"key":"e_1_3_2_3_194_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000500"},{"key":"e_1_3_2_3_195_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0724-8"},{"key":"e_1_3_2_3_196_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2094"},{"key":"e_1_3_2_3_197_1","unstructured":"Murphy KP . Janeways\u2018s Immunobiology (8th Edition). Garland Science Taylor & Francis Group LLC Florence KY USA (2012)"},{"key":"e_1_3_2_3_198_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_3_2_3_199_1","first-page":"S334","volume":"64","author":"Smolen JS","year":"2012","unstructured":"Smolen JS , AletahaD, GrubenD. Remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheum.64(Suppl. 10) , S334 (2012).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_4_2_1","unstructured":"American College of Rheumatology. www.rheumatology.org"},{"key":"e_1_3_2_4_3_1","unstructured":"European League Against Rheumatism. www.eular.org"},{"key":"e_1_3_2_4_4_1","unstructured":"US FDA approval of etanercept for rheumatoid arthritis. Click here for link."},{"key":"e_1_3_2_4_5_1","unstructured":"US FDA approval of tofacitinib for rheumatoid arthritis. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm327152.htm"},{"key":"e_1_3_2_4_6_1","unstructured":"Details of tofacitinib for rheumatoid arthritis by the advisory committee meeting. Click here for link."},{"key":"e_1_3_2_4_7_1","unstructured":"Study of the effect of fostamatinib twice daily on blood pressure in patients with rheumatoid arthritis (Oskira ABPM). http:\/\/clinicaltrials.gov\/show\/NCT01563978"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.13.94","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:39:06Z","timestamp":1715945946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.13.94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":205,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.2217\/imt.13.94"],"URL":"https:\/\/doi.org\/10.2217\/imt.13.94","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}